---
title: "BRIEF: Legend Biotech’s revenue jumps on growing momentum for cancer treatment"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/286290881.md"
description: "生物科技公司 Legend Biotech 周二报告称，第一季度收入同比增长 56%，达到 3.051 亿美元，受益于与强生旗下的 Janssen 单位合作的癌症治疗药物 Carvykti 的强劲销售。该季度 Legend 的收入大部分来自与 Janssen 的合作，约为 2.98 亿美元。Carvykti 的总销售额同比增长 62%，达到 5.97 亿美元。尽管如此，Legend 在最新季度录得净亏损 5430 万美元，亏损幅度缩小近一半。"
datetime: "2026-05-13T16:05:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286290881.md)
  - [en](https://longbridge.com/en/news/286290881.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286290881.md)
---

# BRIEF: Legend Biotech’s revenue jumps on growing momentum for cancer treatment

Drug developer **Legend Biotech Corp.** (LEGN.US) on Tuesday **reported** its revenue rose 56% year-on-year to $305.1 million in the first quarter, as it reaped the benefit of strong sales for Carvykti, its cancer treatment that it is commercializing with **Johnson & Johnson’s** (JNJ.US) Janssen unit.

The vast majority of Legend’s revenue for the quarter, about $298 million, came from its Janssen collaboration, which currently sells Carvykti in 18 global markets, including recent launches in Poland, the Czech Republic and Australia. Total Carvykti sales during the quarter grew 62% year-on-year to $597 million.

Legend recorded a net loss of $54.3 million in the latest quarter, narrowing by nearly half from a $101 million loss a year earlier. Its adjusted loss for the quarter narrowed by more than half to $10.5 million from $27 million a year earlier.

Legend Biotech’s New York-listed stock rose 10.5% on Tuesday after the results were published. The stock is up 31% year-to-date.

_By Doug Young_

_To subscribe to Bamboo Works weekly free newsletter, click_ _here_

### 相关股票

- [LEGN.US](https://longbridge.com/zh-CN/quote/LEGN.US.md)
- [IBBQ.US](https://longbridge.com/zh-CN/quote/IBBQ.US.md)
- [PBE.US](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/zh-CN/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [ARKG.US](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/zh-CN/quote/BBH.US.md)
- [JNJ.US](https://longbridge.com/zh-CN/quote/JNJ.US.md)

## 相关资讯与研究

- [瑞银上调爵士制药评级：核心业务韧性强劲，新药 Ziihera 成增长引擎](https://longbridge.com/zh-CN/news/286920691.md)
- [“搞钱”，才是 Revolution 千亿神话密码](https://longbridge.com/zh-CN/news/286888792.md)
- [Tevogen Bio Q1 运营亏损收窄 48%，推进 AI 平台与细胞疗法管线](https://longbridge.com/zh-CN/news/287086570.md)
- [Scholar Rock 将出席杰富瑞全球医疗保健大会，聚焦 SMA 新药 apitegromab 关键审批](https://longbridge.com/zh-CN/news/287069556.md)
- [CAR-T 迎接新时代](https://longbridge.com/zh-CN/news/286999381.md)